Real-World Treatment Patterns and Clinical Outcomes Among Patients With Triple-Class-Exposed and BCMA-Exposed Multiple Myeloma Within the United States.

ABSTRACT:

Introduction

A novel therapy for heavily pretreated triple-class-exposed multiple myeloma (TCE MM) is B-cell maturation antigen (BCMA)-targeted immunotherapy. While the number of TCE+BCMA-exposed patients is growing, real-world data for this group are limited.

Methods

We present real-world data from patients with TCE+BCMA-exposed MM who initiated a subsequent line of therapy (LOT) using a US-based claims database, Komodo's Healthcare Map.

Results

We identified 656 TCE+BCMA-exposed patients; mean age was 66.5 years. Time from MM diagnosis to index was 5.4 years; mean number of prior LOTs was 5.9. The most prevalent prior therapy received within each drug class was daratumumab (98.5%), pomalidomide (86.0%), carfilzomib (85.8%) and belantamab mafodotin (74.5%). A total o

SUBMITTER: Mian HS 

PROVIDER: S-EPMC12455680 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature